Myositis Pipeline Insight Report 2023 (Updated)

September 15 19:56 2023
Myositis Pipeline Insight Report 2023 (Updated)

DelveInsight’s, “Myositis Pipeline Insight 2023,” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Myositis pipeline landscape. It covers the Myositis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Myositis Pipeline Report

  • DelveInsight’s Myositis pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Myositis treatment.
  • The leading companies working in the Myositis Market include Pharmaceuticals, Janssen Research & Development, LLC, Pfizer, Abcuro, Inc., Orphazyme, Bristol-Myers Squibb, Kezar Life Sciences, Inc., Horizon Therapeutics, Paean Biotechnology Inc., Alexion Pharmaceuticals, ImmunoForge, JN Biosciences, Merck KGaA, and others.
  • Promising Myositis Pipeline Therapies in the various stages of development includes ABC008, Daxdilimab, BYM338 (Bimagrumab), BYM338, Arimoclomol, Nipocalimab, Glucocorticoids, and others.
  • On August 2023, Abcuro Inc. announced a study of Phase 2 & 3 clinical trials for ABC008. A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis.
  • On August 2023, Horizon Therapeutics Ireland DAC announced a study of Phase 2 Clinical Trials for Daxdilimab. To evaluate the effect of daxdilimab compared with placebo in reducing disease activity at Week 24.

 

Request a sample and discover the recent advances in Myositis Treatment Drugs @ Myositis Pipeline Report

 

The Myositis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Myositis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Myositis clinical trial landscape.

 

Myositis Overview

The term “myositis” refers to a general inflammation or swelling of the muscle. Many people have experienced sore muscles after vigorous exercise, a condition that is temporary and improves with rest.

 

Find out more about Myositis Treatment Drugs @ Drugs for Myositis Treatment

 

Myositis Emerging Drugs Profile

  • Lenabasum: Corbus Pharmaceuticals
  • Nipocalimab: Janssen Research & Development, LLC

 

Myositis Pipeline Therapeutics Assessment

There are approx. 20+ key companies which are developing the therapies for Myositis. The Myositis companies which have their Myositis drug candidates in the most advanced stage, i.e. phase III include, Corbus Pharmaceuticals.

 

Learn more about the emerging Myositis Pipeline Therapies @ Myositis Clinical Trials Assessment

 

Scope of the Myositis Pipeline Report

  • Coverage- Global
  • Allergic Conjunctivitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Allergic Conjunctivitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Myositis Companies- Corbus Pharmaceuticals, Janssen Research & Development, LLC, Pfizer, Abcuro, Inc., Orphazyme, Bristol-Myers Squibb, Kezar Life Sciences, Inc., Horizon Therapeutics, Paean Biotechnology Inc., Alexion Pharmaceuticals, ImmunoForge, JN Biosciences, Merck KGaA, and others.
  • Myositis Pipeline Therapies- ABC008, Daxdilimab, BYM338 (Bimagrumab), BYM338, Arimoclomol, Nipocalimab, Glucocorticoids, and others.

 

Dive deep into rich insights for new drugs for Myositis Treatment, Visit @ Myositis Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Myositis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Myositis – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Lenabasum: Corbus Pharmaceuticals
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Nipocalimab: Janssen Research & Development, LLC
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Drug Name: Company Name
  15. Drug profiles in the detailed report…..
  16. Inactive Products
  17. Myositis Key Companies
  18. Myositis Key Products
  19. Myositis- Unmet Needs
  20. Myositis- Market Drivers and Barriers
  21. Myositis- Future Perspectives and Conclusion
  22. Myositis Analyst Views
  23. Myositis Key Companies
  24. Appendix

 

For further information on the Myositis Pipeline therapeutics, reach out to Myositis Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting